IL316386A - Macrocyclic tracking of ATP citrate lyase - Google Patents
Macrocyclic tracking of ATP citrate lyaseInfo
- Publication number
- IL316386A IL316386A IL316386A IL31638624A IL316386A IL 316386 A IL316386 A IL 316386A IL 316386 A IL316386 A IL 316386A IL 31638624 A IL31638624 A IL 31638624A IL 316386 A IL316386 A IL 316386A
- Authority
- IL
- Israel
- Prior art keywords
- citrate lyase
- atp citrate
- macrocyclic inhibitors
- macrocyclic
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263337344P | 2022-05-02 | 2022-05-02 | |
| US202363481045P | 2023-01-23 | 2023-01-23 | |
| PCT/US2023/020546 WO2023215220A1 (en) | 2022-05-02 | 2023-05-01 | Macrocyclic inhibitors of atp citrate lyase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316386A true IL316386A (en) | 2024-12-01 |
Family
ID=86776394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316386A IL316386A (en) | 2022-05-02 | 2023-05-01 | Macrocyclic tracking of ATP citrate lyase |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250289793A1 (enExample) |
| EP (1) | EP4519251A1 (enExample) |
| JP (1) | JP2025515002A (enExample) |
| KR (1) | KR20250004873A (enExample) |
| CN (1) | CN119137107A (enExample) |
| AU (1) | AU2023264491A1 (enExample) |
| CA (1) | CA3251749A1 (enExample) |
| IL (1) | IL316386A (enExample) |
| WO (1) | WO2023215220A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL328133A (en) * | 2023-11-01 | 2026-06-01 | Esperion Therapeutics Inc | Macrocyclic inhibitors of atp citrate lyase |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| WO2020097408A1 (en) * | 2018-11-09 | 2020-05-14 | Nimbus Artemis, Inc. | Acly inhibitors and uses thereof |
| CN115677616B (zh) * | 2021-11-03 | 2024-10-18 | 中国药科大学 | 大环磺酰胺类化合物及其制备方法和医药用途 |
-
2023
- 2023-05-01 WO PCT/US2023/020546 patent/WO2023215220A1/en not_active Ceased
- 2023-05-01 CA CA3251749A patent/CA3251749A1/en active Pending
- 2023-05-01 JP JP2024564484A patent/JP2025515002A/ja active Pending
- 2023-05-01 EP EP23731394.5A patent/EP4519251A1/en active Pending
- 2023-05-01 IL IL316386A patent/IL316386A/en unknown
- 2023-05-01 KR KR1020247039451A patent/KR20250004873A/ko active Pending
- 2023-05-01 CN CN202380038044.0A patent/CN119137107A/zh active Pending
- 2023-05-01 US US18/862,295 patent/US20250289793A1/en active Pending
- 2023-05-01 AU AU2023264491A patent/AU2023264491A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023215220A1 (en) | 2023-11-09 |
| EP4519251A1 (en) | 2025-03-12 |
| US20250289793A1 (en) | 2025-09-18 |
| CN119137107A (zh) | 2024-12-13 |
| AU2023264491A1 (en) | 2024-10-31 |
| CA3251749A1 (en) | 2023-11-09 |
| KR20250004873A (ko) | 2025-01-08 |
| JP2025515002A (ja) | 2025-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202212146B (en) | Inhibitors of nek7 kinase | |
| PL4284511T3 (pl) | Azachinoliny jako inhibitory cd38 | |
| IL297929B2 (en) | Iminosulfonone inhibitors of ENPP1 | |
| IL317736A (en) | Compounds as AXL inhibitors | |
| IL310812A (en) | SOLID FORMS OF SPIROTRICYCLIC APOL1 INHIBITORS AND METHODS OF USING THEM | |
| HUE072626T2 (hu) | Ciliopathiák kezelése glükozilceramid-szintáz (GCS) inhibitorok alkalmazásával | |
| GB2628952B (en) | Active magnetic ranging while drilling | |
| IL313548A (en) | MET kinase inhibitors | |
| IL314397A (en) | CDK4/6 kinase inhibitors | |
| IL317768A (en) | Methods for preparing tailored BTK inhibitors | |
| GB202200070D0 (en) | Method of culture | |
| IL313735A (en) | Salts and solid forms of Pajfer inhibitor and processes for their preparation | |
| IL308071A (en) | Process for preparing NLRP3 inhibitors | |
| EP4263520A4 (en) | HETEROCYCLIC PCSK9 INHIBITORS | |
| PL4192812T3 (pl) | Inhibitory transglutaminaz | |
| IL308216A (en) | Jak1 pathway inhibitors for the treatment of prurigo nodularis | |
| IL321161A (en) | Solid forms of naphthyridine compounds | |
| IL326113A (en) | Methods of using factor b inhibitors | |
| GB202215863D0 (en) | Preparation of neosaxitoxin | |
| IL308513A (en) | ALK2 kinase inhibitors containing imidazoles | |
| IL304191A (en) | elagolix administration methods | |
| IL319472A (en) | Physical forms of PRC2 inhibitor | |
| EP4405346A4 (en) | SMALL MOLECULE INHIBITORS OF TEAD-YAP | |
| GB202112421D0 (en) | Method of deposition | |
| GB202008892D0 (en) | Method of deposition |